GSK pulls EMA Tafinlar/Mekinist application

Share this article:
GSK cancer drug combination approved
GSK backed off of its EU request because it wanted to wait for more data

GlaxoSmithKline announced Wednesday that it pulled its request to have the European Medicines Agency review its request to approve Mekinist and Tafinlar as a duo to combat unresectable or metastatic melanoma with a BRAF V600 mutation.

The FDA approved this tandem use in January, but GSK said in a statement that it backed off of its EU request because it wanted to wait for data from an ongoing Phase-III clinical trial to come in first. Prompting the delay: The EMA's Committee for Medicinal Products for Human Use told the drugmaker that there wasn't enough data to make a “positive benefit-risk balance.”

GlaxoSmithKline says it will re-file the review request once it has sufficient data on hand.

The FDA's approval made Mekinist and Tafinlar the first combination oral therapy for these conditions.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union